Page 1

RD Gente , Saúde e Bem - estar . RaiaDrogasil S.A. EARNINGS RELEASE 2Q21 Raia Rala DROGASIL + DROGASIL São Paulo , August 10 , 2021. RD - People , Health and Well - being ( Raia Drogasil S.A. – B3 : RADL3 ) announces today its results for the 2nd quarter of 2021 ( 2Q21 ) . The Company's parent company and consolidated interim financial statements for the periods ended June 30 , 2021 and 2020 have been prepared in accordance with the accounting practices adopted in Brazil , including the rules issued by the Brazilian Securities Commission ( CVM ) , the Brazilian Accounting Standards - General Technical ( NBC TG ) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee ( CPC ) , and are in conformity with the International Financial Reporting Standards ( IFRS ) issued by the International Accounting Standards Board ( IASB ) , and provide all the significant information related solely to the interim financial statements , which is consistent with the information used by management . The financial statements were prepared in Reais and all growth rates , unless otherwise stated , relate to the same period of 2020 . Since 2019 , our financial statements have been prepared in accordance with IFRS 16. In order to better represent the economics of the business , the figures in this report are presented under IAS 17 / CPC 06 , the previous reporting standard . Reconciliation with IFRS 16 can be found on pages 12 and 13 . QUARTERLY HIGHLIGHTS : > PHARMACIES : 2,374 units in operation ( 62 openings and 7 closures ) > > > MARKET SHARE : 1.1 percentage point increase , with gains in every region > GROSS REVENUE : R $ 6.2 billion , 32.3 % growth vs. the 2Q20 and 40.6 % vs. the 2Q19 CONTRIBUTION MARGIN * : 10.8 % , 81 % of growth and 2.9 p.p. of margin expansion ADJUSTED EBITDA : R $ 497.1 million , an 8.0 % EBITDA margin and 114 % growth > ADJUSTED NET INCOME : R $ 232.0 million , 3.7 % of net margin and 276 % growth > > CASH FLOW : R $ 302.1 million negative free cash flow , R $ 387.3 million total cash consumption HEALTH PLATFORM : Announcement of Vitat , new platform for the promotion of integral health * Margin before corporate overhead ( gross profit - selling expenses ) 2Q20 3Q20 4Q20 1Q21 2Q21 2,159 2,220 2,299 2,319 2,374 Organic Openings 55 64 82 40 62 Closures 0 ( 3 ) ( 3 ) ( 20 ) ( 7 ) 4Bio 3 3 4 4 4 # of Stores - Pharmacies + 4Bio 2,162 2,223 2,303 2,323 2,378 Headcount ( EOP ) Pharmacist Count ( EOP ) 42,115 8,414 43,223 44,631 45,532 8,658 8,788 9,088 47,208 9,346 RADL3 R $ 26.70 / share NUMBER OF SHARES 1,651,930,000 MARKET CAP R $ 44,107 ( million ) CLOSING August 9th , 2021 IR CONTACTS : Eugênio De Zagottis Fernando Spinelli André Stolfi Igor Spricigo SITE : ir.rd.com.br E - MAIL : ri@rd.com.br Summary ( R $ thousand ) # of Pharmacies # of Tickets ( 000 ) Gross Revenue Gross Profit % of Gross Revenues 52,308 60,298 67,098 65,660 66,911 4,721,872 5,384,230 5,868,052 5,979,508 6,245,163 1,320,122 1,494,996 1,634,213 1,641,852 1,797,052 28.0 % 27.8 % 27.8 % 27.5 % 28.8 % Adjusted EBITDA 231,811 % of Gross Revenues 4.9 % 397,159 7.4 % 430,843 7.3 % 415,855 7.0 % 497,115 8.0 % Adjusted Net Income % of Gross Revenues 61,688 172,871 1.3 % 3.2 % 213,672 3.6 % 177,947 3.0 % 232,022 3.7 % Net Income 60,210 % of Gross Revenues 1.3 % 174,717 3.2 % 198,492 3.4 % 188,789 3.2 % 266,443 4.3 % Free Cash Flow ( 437,520 ) 351,792 425,112 ( 131,972 ) ( 302,106 ) IBRX50 B3 IBRA B3 IGCT B3 ITAG B3 IGC - NMB3 ICON B3 MLCXB3 ICO2 B3 RADL B3 LISTED NM